Comparison of SARS-CoV-2 Antibody Response by Age Among Recipients of the BNT162b2 vs the mRNA-1273 Vaccine
Nathan E. Richards, Behnam Keshavarz, Lisa J. Workman, Michael R. Nelson, Thomas A.E. Platts‐Mills, Jeffrey M. Wilson
Abstract
g/mL [95% CI, 48.8-71.4 g/mL]) and age-similar peers who received mRNA-1273 (71.8 g/mL [95% CI, 58.1-88.8 g/mL]) (Figure).
Topics & Concepts
ImmunogenicityMedicineAntibodySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)Antibody responseNeutralizing antibody2019-20 coronavirus outbreakMessenger RNACohortImmunologyVirologyInternal medicineBiologyGeneInfectious disease (medical specialty)OutbreakDiseaseBiochemistrySARS-CoV-2 and COVID-19 ResearchViral Infections and Immunology ResearchCOVID-19 Clinical Research Studies